Clinical trialNCT01122329CompletedPhase 4Interventional

A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease

SponsorUniversity of California, Los AngelesEnrollment17Alzheimer Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will examine the brain metabolic effects of AC-1202 (Axona®), a medical food for Alzheimer's disease. Subjects who meet entry criteria will undergo H215O positron emission tomography prior to and 90 minutes after consumption of Axona® at baseline and then again after 45 days of treatment. Cognitive testing will also be conducted at baseline and day 45.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Cathy Lee, PhD
Mary S. Easton Center for Alzheimer's Disease Research at UCLA
Study Chair
clinicaltrials.gov ↗
Dan Silverman, MD, PhD
UCLA Department of Molecular and Medical Pharmacology
Study Chair
clinicaltrials.gov ↗
Ellen Woo, PhD
Mary S. Easton Center for Alzheimer's Disease Research at UCLA
Study Chair
clinicaltrials.gov ↗
Jeffrey Cummings, MD
Mary S. Easton Center for Alzheimer's Disease Research at UCLA
Study Chair
clinicaltrials.gov ↗
John Ringman, MD
Mary S. Easton Center for Alzheimer's Disease Research at UCLA
Study ChairKOL profile →
clinicaltrials.gov ↗
Joshua Grill, PhD
Mary S. Easton Center for Alzheimer's Disease Research at UCLA
Principal Investigator
clinicaltrials.gov ↗
Maryam Beigi, MD
Mary S. Easton Center for Alzheimer's Disease Research at UCLA
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

200 Medical Plaza, Ucla Medical Center
Los Angeles, California, United States
Center for Neurotherapeutics at Ucla
Los Angeles, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2010
Primary completion: 31 Jan 2015
Completion: 31 Jan 2015
Last update posted: 23 Mar 2015
Registered enrollment: 17
Registry id: NCT01122329

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.